Loading...

Sangamo Therapeutics

Nasdaq:SGMO
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SGMO
Nasdaq
$1B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Sangamo Therapeutics, Inc. focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The last earnings update was 76 days ago. More info.


Add to Portfolio Compare Print
  • Sangamo Therapeutics has significant price volatility in the past 3 months.
SGMO Share Price and Events
7 Day Returns
-2.7%
NasdaqGS:SGMO
-0.5%
US Biotechs
0.7%
US Market
1 Year Returns
-44.8%
NasdaqGS:SGMO
-8.4%
US Biotechs
-8.1%
US Market
SGMO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sangamo Therapeutics (SGMO) -2.7% 10.7% -13.1% -44.8% 70.2% -42.8%
US Biotechs -0.5% 19.3% 5.8% -8.4% 8.9% 15.3%
US Market 0.7% 10.2% -1% -8.1% 38.8% 38.9%
1 Year Return vs Industry and Market
  • SGMO underperformed the Biotechs industry which returned -8.4% over the past year.
  • SGMO underperformed the Market in United States of America which returned -8.1% over the past year.
Price Volatility
SGMO
Industry
5yr Volatility vs Market

SGMO Value

 Is Sangamo Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sangamo Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $11.06.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sangamo Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sangamo Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:SGMO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-0.68
NasdaqGS:SGMO Share Price ** NasdaqGS (2019-01-23) in USD $11.06
United States of America Biotechs Industry PE Ratio Median Figure of 32 Publicly-Listed Biotechs Companies 26.07x
United States of America Market PE Ratio Median Figure of 3,026 Publicly-Listed Companies 16.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sangamo Therapeutics.

NasdaqGS:SGMO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:SGMO Share Price ÷ EPS (both in USD)

= 11.06 ÷ -0.68

-16.32x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sangamo Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Sangamo Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Sangamo Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGS:SGMO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -16.32x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
-1.9%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 25 Publicly-Listed Biotechs Companies 2.35x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.26x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sangamo Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sangamo Therapeutics's assets?
Raw Data
NasdaqGS:SGMO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $3.73
NasdaqGS:SGMO Share Price * NasdaqGS (2019-01-23) in USD $11.06
United States of America Biotechs Industry PB Ratio Median Figure of 400 Publicly-Listed Biotechs Companies 2.89x
United States of America Market PB Ratio Median Figure of 5,102 Publicly-Listed Companies 1.75x
NasdaqGS:SGMO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:SGMO Share Price ÷ Book Value per Share (both in USD)

= 11.06 ÷ 3.73

2.96x

* Primary Listing of Sangamo Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sangamo Therapeutics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Sangamo Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Sangamo Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SGMO Future Performance

 How is Sangamo Therapeutics expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-1.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sangamo Therapeutics expected to grow at an attractive rate?
  • Sangamo Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Sangamo Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.
  • Sangamo Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:SGMO Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:SGMO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts -1.9%
NasdaqGS:SGMO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 31.7%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 21.9%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.2%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.6%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:SGMO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:SGMO Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 471 71 2
2022-12-31 67 -228 2
2021-12-31 50 -207 2
2020-12-31 66 -161 -162 3
2019-12-31 86 -131 -100 7
2018-12-31 80 51 -67 7
NasdaqGS:SGMO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 71 60 -63
2018-06-30 59 72 -62
2018-03-31 46 6 -58
2017-12-31 37 11 -55
2017-09-30 32 16 -51
2017-06-30 23 14 -58
2017-03-31 19 -59 -72
2016-12-31 19 -66 -72
2016-09-30 20 -63 -76
2016-06-30 25 -60 -66
2016-03-31 30 -52 -52
2015-12-31 40 -34 -41

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sangamo Therapeutics's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Sangamo Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:SGMO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Sangamo Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:SGMO Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.76 1.84 -0.33 2.00
2022-12-31 -1.77 -1.64 -1.90 2.00
2021-12-31 -1.74 -1.62 -1.85 2.00
2020-12-31 -1.40 -1.20 -1.69 3.00
2019-12-31 -0.97 -0.49 -1.32 7.00
2018-12-31 -0.73 -0.61 -0.88 7.00
NasdaqGS:SGMO Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -0.68
2018-06-30 -0.71
2018-03-31 -0.71
2017-12-31 -0.70
2017-09-30 -0.69
2017-06-30 -0.81
2017-03-31 -1.02
2016-12-31 -1.02
2016-09-30 -1.08
2016-06-30 -0.94
2016-03-31 -0.74
2015-12-31 -0.58

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sangamo Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Sangamo Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sangamo Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SGMO Past Performance

  How has Sangamo Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sangamo Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sangamo Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Sangamo Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sangamo Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Sangamo Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sangamo Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:SGMO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 70.69 -62.76 39.85
2018-06-30 58.94 -62.27 35.28
2018-03-31 45.78 -58.12 30.01
2017-12-31 36.57 -54.57 27.20
2017-09-30 32.41 -51.10 22.60
2017-06-30 23.42 -57.71 23.20
2017-03-31 18.87 -71.80 22.15
2016-12-31 19.39 -71.66 20.23
2016-09-30 19.59 -76.05 22.26
2016-06-30 25.33 -66.33 19.80
2016-03-31 29.99 -51.88 19.82
2015-12-31 39.54 -40.70 19.20
2015-09-30 45.37 -31.01 18.64
2015-06-30 49.22 -29.31 17.81
2015-03-31 51.25 -24.16 16.77
2014-12-31 45.87 -26.42 15.68
2014-09-30 37.79 -30.24 15.55
2014-06-30 31.08 -28.84 14.98
2014-03-31 27.63 -27.31 14.14
2013-12-31 24.13 -26.62 13.80
2013-09-30 26.20 -21.96 12.61
2013-06-30 25.40 -21.60 12.59
2013-03-31 23.04 -21.88 12.21
2012-12-31 21.66 -22.26 12.14
2012-09-30 17.47 -25.15 12.36
2012-06-30 14.42 -28.91 12.81 -16.38
2012-03-31 11.36 -33.44 13.75 -8.26

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sangamo Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sangamo Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sangamo Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sangamo Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sangamo Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SGMO Health

 How is Sangamo Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sangamo Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sangamo Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sangamo Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sangamo Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Sangamo Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sangamo Therapeutics Company Filings, last reported 3 months ago.

NasdaqGS:SGMO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 379.91 0.00 458.57
2018-06-30 387.87 0.00 539.45
2018-03-31 182.37 0.00 229.53
2017-12-31 187.90 0.00 243.31
2017-09-30 186.65 0.00 236.70
2017-06-30 194.04 0.00 249.91
2017-03-31 125.68 0.00 129.27
2016-12-31 136.20 0.00 142.54
2016-09-30 143.84 0.00 145.58
2016-06-30 160.02 0.00 172.28
2016-03-31 179.41 0.00 187.58
2015-12-31 192.44 0.00 209.00
2015-09-30 203.56 0.00 219.33
2015-06-30 199.94 0.00 214.23
2015-03-31 207.49 0.00 195.90
2014-12-31 206.63 0.00 178.96
2014-09-30 210.14 0.00 162.42
2014-06-30 214.36 0.00 193.66
2014-03-31 217.43 0.00 213.43
2013-12-31 121.71 0.00 92.81
2013-09-30 126.14 0.00 120.22
2013-06-30 59.38 0.00 47.28
2013-03-31 61.59 0.00 57.27
2012-12-31 64.90 0.00 63.55
2012-09-30 66.40 0.00 57.90
2012-06-30 70.23 0.00 59.64
2012-03-31 74.34 0.00 79.70
  • Sangamo Therapeutics has no debt.
  • Sangamo Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sangamo Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Sangamo Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -36.4% each year.
X
Financial health checks
We assess Sangamo Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sangamo Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SGMO Dividends

 What is Sangamo Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sangamo Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of Sangamo Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sangamo Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sangamo Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:SGMO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 2.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1986 Stocks 2.6%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.9%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:SGMO Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sangamo Therapeutics has not reported any payouts.
  • Unable to verify if Sangamo Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sangamo Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sangamo Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Sangamo Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Sangamo Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sangamo Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sangamo Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SGMO Management

 What is the CEO of Sangamo Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sandy Macrae
COMPENSATION $1,795,856
AGE 55
TENURE AS CEO 2.6 years
CEO Bio

Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch.B, Ph.D., MRCP, has been the Chief Executive Officer and President of Sangamo Therapeutics, Inc. since June 1, 2016. Dr. Macrae has nearly 20 years of experience in the pharmaceutical industry across a wide range of therapeutic areas in Europe, the United States and emerging markets. Since 2012, he has served as global medical officer of Takeda Pharmaceuticals, where he established and led the global medical office, which encompasses medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences and knowledge and informatics. From 2001 to 2012, Dr. Macrae held roles of increasing responsibility at Glaxo SmithKline (GSK), where his last role was as senior vice president, emerging markets research and development (R&D). In that position, he provided expertise and resources to create a first-of-its-kind group to expand GSK's global reach by providing R&D strategies, clinical development and regulatory resources to enter emerging markets and Asia-Pacific. Earlier in his career at GSK, Dr. Macrae was vice president, business development. In that position, he was responsible for scientific assessment and business development project leadership for the neurology, psychiatry, cardiovascular and metabolic therapeutic areas. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology. He has been a Director of Sangamo Therapeutics, Inc. since June 2016. He is a member of the Royal College of Physicians. He was a Wellcome Trust Advance Training Fellow at Hammersmith Hospital in London and a Howard Hughes Research Associate at Duke University Medical Center in Durham, N.C., where he conducted post-doctoral research in molecular pharmacology under the guidance of Nobel Prize winner Robert Lefkowitz. Dr. Macrae earned his Ph.D. in molecular genomics at King's College, Cambridge, under the supervision of Nobel Prize-winner Sydney Brenner. Dr. Macrae received his B.Sc. in pharmacology with first-class honors and his M.B., Ch.B. with honors from Glasgow University.

CEO Compensation
  • Sandy's compensation has been consistent with company performance over the past year.
  • Sandy's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Sangamo Therapeutics management team in years:

1.9
Average Tenure
45.5
Average Age
  • The average tenure for the Sangamo Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Sandy Macrae

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
55
TENURE
2.6 yrs

Kathy Yi

TITLE
Senior VP & CFO
COMPENSATION
$1M
AGE
46
TENURE
1.9 yrs

Ed Conner

TITLE
Senior VP & Chief Medical Officer
COMPENSATION
$541K
AGE
45
TENURE
2.2 yrs

Ed Rebar

TITLE
Senior VP & CTO
TENURE
0.5 yrs

McDavid Stilwell

TITLE
Vice President of Corporate Communications & Investor Relations
TENURE
2.2 yrs

Heather Turner

TITLE
Senior VP
AGE
45
TENURE
0.9 yrs

Heather Erickson

TITLE
Chief of Staff
TENURE
2.5 yrs

Andy Ramelmeier

TITLE
Senior VP and Chief Manufacturing & Quality Officer
TENURE
0.8 yrs

Stéphane Boissel

TITLE
Executive VP of Corporate Strategy
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Sangamo Therapeutics board of directors in years:

7.5
Average Tenure
64.5
Average Age
  • The tenure for the Sangamo Therapeutics board of directors is about average.
Board of Directors

H. Parker

TITLE
Chair of the Board
COMPENSATION
$128K
AGE
62

Sandy Macrae

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
55
TENURE
2.6 yrs

Steven Mento

TITLE
Independent Director
COMPENSATION
$103K
AGE
66
TENURE
13.7 yrs

Roger Jeffs

TITLE
Director
COMPENSATION
$188K
AGE
56
TENURE
1.6 yrs

Kevin Struhl

TITLE
Member of Scientific Advisory Board

Aaron Klug

TITLE
Member of Scientific Advisory Board
AGE
91

Mike Gilman

TITLE
Member of Scientific Advisory Board
AGE
63
TENURE
12.5 yrs

Gabor Rubanyi

TITLE
Member of Scientific Advisory Board
AGE
71

Judy Campisi

TITLE
Member of Scientific Advisory Board

Barrie Carter

TITLE
Member of Scientific Advisory Board
AGE
73
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Sangamo Therapeutics insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
16. Nov 18 Buy H. Parker Individual 14. Nov 18 14. Nov 18 2,000 $9.00 $18,002
07. Sep 18 Buy H. Parker Individual 07. Sep 18 07. Sep 18 2,000 $13.52 $27,040
07. Sep 18 Buy Roger Jeffs Individual 07. Sep 18 07. Sep 18 7,408 $13.56 $100,487
X
Management checks
We assess Sangamo Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sangamo Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SGMO News

Simply Wall St News

What Investors Should Know About Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Financial Strength

However, the trade-off is SGMO will have to follow strict debt obligations which will reduce its financial flexibility. … Zero-debt can alleviate some risk associated with the company meeting debt obligations, but this doesn’t automatically mean SGMO has outstanding financial strength. … Is SGMO right in choosing financial flexibility over lower cost of capital.

Simply Wall St -

How Many Insiders Bought Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares?

We often see insiders buying up shares in companies that perform well over the long term. … The Last 12 Months Of Insider Transactions At Sangamo Therapeutics. … In total, Sangamo Therapeutics insiders bought more than they sold over the last year

Simply Wall St -

Do Institutions Own Shares In Sangamo Therapeutics Inc (NASDAQ:SGMO)?

If you want to know who really controls Sangamo Therapeutics Inc (NASDAQ:SGMO), then you'll have to look at the makeup of its share registry. … It has a market capitalization of US$1.1b, which means it would generally expect to see some institutions on the share registry. … institutions are noticeable on the share registry.

Simply Wall St -

Is Sangamo Therapeutics Inc (NASDAQ:SGMO) Cheap And High Growth?

is a healthcare company operating in an industry, … The demand for new drug development to meet new or persistent chronic illnesses, as well as the ongoing need for biotech drugs as Baby Boomers continue to age, are growth drivers for the optimistic outlook for the biotech industry in the long run … Healthcare analysts are forecasting for the entire industry,

Simply Wall St -

When Can We Expect A Profit From Sangamo Therapeutics Inc (NASDAQ:SGMO)?

focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. … The company’s loss has recently broadened since it announced a -US$54.57m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$58.12m, moving it further away from breakeven. … I’ve put together a brief outline of industry analyst expectations for SGMO, its year of breakeven and its implied growth rate.

Simply Wall St -

Was Sangamo Therapeutics Inc's (NASDAQ:SGMO) Earnings Growth Better Than The Industry's?

When Sangamo Therapeutics Inc (NASDAQ:SGMO) announced its most recent earnings (31 December 2017), I did two things: looked at its past earnings track record, then look at what is happening in the industry. … I look at data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … For Sangamo Therapeutics, its latest trailing-twelve-month earnings is -US$54.57M, which, relative to the prior year's level, has become less negative.

Simply Wall St -

What Should You Know About Sangamo Therapeutics Inc's (NASDAQ:SGMO) Future?

The latest earnings release Sangamo Therapeutics Inc's (NASDAQ:SGMO) announced in December 2017 indicated company earnings became less negative compared to the previous year's level as a result of recent tailwinds Below is my commentary, albeit very simple and high-level, on how market analysts view Sangamo Therapeutics's earnings growth outlook over the next few years and whether the future looks brighter. … See our latest analysis for Sangamo Therapeutics Market analysts' consensus outlook for the coming year seems buoyant, with earnings becoming less negative, arriving at -US$520.33K in 2019. … This means that, we can assume Sangamo Therapeutics will chip away at a rate of -14.21% every year for the next few years.

Simply Wall St -

What Are Analysts Saying About Sangamo Therapeutics Inc's (NASDAQ:SGMO) Growth?

Based on Sangamo Therapeutics Inc's (NASDAQ:SGMO) earnings update in December 2017, the consensus outlook from analysts appear highly confident, with earnings expected to grow by a high double-digit of 76.68% in the upcoming year, relative to the previous 5-year average growth rate of -14.40%. … To reduce the year-on-year volatility of analyst earnings forecast, I've inserted a line of best fit through the expected earnings figures to determine the annual growth rate from the slope of the line. … NasdaqGS:SGMO Future Profit Mar 13th 18 From the current net income level of -US$54.57M and the final forecast of -US$72.93M by 2021, the annual rate of growth for SGMO’s earnings is -12.00%.

Simply Wall St -

Sangamo Therapeutics Inc (NASDAQ:SGMO): Financial Strength Analysis

Check out our latest analysis for Sangamo Therapeutics Can SGMO service its debt comfortably? … For Sangamo Therapeutics, investors should not worry about its debt levels because the company has none! … Since Sangamo Therapeutics doesn’t have any debt on its balance sheet, it doesn’t have any solvency issues, which is a term used to describe the company’s ability to meet its long-term obligations.

Simply Wall St -

Should You Be Concerned About Sangamo Therapeutics Inc's (NASDAQ:SGMO) Shareholders?

View our latest analysis for Sangamo Therapeutics NasdaqGS:SGMO Ownership_summary Feb 12th 18 Institutional Ownership In SGMO's case, institutional ownership stands at 66.04%, significant enough to cause considerable price moves in the case of large institutional transactions, especially when there is a low level of public shares available on the market to trade. … General Public Ownership A substantial ownership of 32.11% in SGMO is held by the general public. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions.

Simply Wall St -

SGMO Company Info

Map
Description

Sangamo Therapeutics, Inc. focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company’s zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for Hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); preclinical programs in other LSDs; and research stage programs in central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and Shire International GmbH to develop preclinical development program in Huntington’s disease, as well as license agreements with Sigma-Aldrich Corporation to develop laboratory research reagents and Dow AgroSciences, LLC to modify the protein expression of plant cells and plants. The company also has a research collaboration and license agreement with Pfizer Inc; and collaboration with Kite for developing ex vivo cell therapies in oncology. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.

Details
Name: Sangamo Therapeutics, Inc.
SGMO
Exchange: NasdaqGS
Founded: 1995
$1,130,167,993
102,092,863
Website: http://www.sangamo.com
Address: Sangamo Therapeutics, Inc.
501 Canal Boulevard,
Richmond,
California, 94804,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS SGMO Common Stock Nasdaq Global Select US USD 06. Apr 2000
DB GBY Common Stock Deutsche Boerse AG DE EUR 06. Apr 2000
LSE 0R1D Common Stock London Stock Exchange GB USD 06. Apr 2000
Number of employees
Current staff
Staff numbers
234
Sangamo Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/01/23 23:41
End of day share price update: 2019/01/23 00:00
Last estimates confirmation: 2019/01/04
Last earnings filing: 2018/11/08
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.